Abstract: The present invention relates to a method for preparing lymphoid progenitors. The inventors took advantage of their original and relevant Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome (WS) model and the access to blood samples from five WS patients to investigate the impact of CXCR4 desensitization on BM and extra-medullary (i.e. splenic) hematopoiesis and hematopoietic stem and progenitor cells (HSPCs) recirculation. They developed, for the first time, an original in vitro system permitting to selectively expand HSPCs to obtain lymphoid progenitors by using an original cocktail of cytokines. In particular, the present invention relates to an in vitro method for preparing lymphoid progenitors by culturing HSPCs in an appropriate culture medium comprising an effective amount of a cocktail of cytokines consisting in SCF, IL-3, IL-6, IL-7, Flt-3, and CXCL12.

Abstract: A dust-proof covering element is provided to close a projection aperture located in the dashboard of a vehicle and through which the information-carrying source light beam projected by the projecting module of a head-up display device passes on its way to a partially reflective return element. The covering element comprises a transparent carrier and an optical coating placed on one of the faces of the carrier; wherein, the optical coating comprises a metal layer with plasmonic properties, said metal layer being endowed with an array of subwavelength nanoperforations, and being configured to allow the extraordinary transmission of one or more restricted bands of wavelengths of the visible spectrum that are centered on the one or more wavelengths of the light beam projected by the projecting module.

Abstract: Peptides endowed with an anti-inflammatory, anti-angiogenic and/or antimicrobial activity, a medicament or a pharmaceutical composition including such peptides, and the use thereof in the prevention or treatment of inflammatory diseases, and more particularly inflammatory diseases due to or associated with microbial infections, or in the prevention or treatment of angiogenesis-related diseases.

Abstract: The invention concerns a Reg3? polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for use in the protection of oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide and their use. The inventors have shown that an increase in the concentration of the h Reg3? lectin into the gastrointestinal tract (GIT) lumen of hReg3?-transgenic mice induced significant changes in the composition of the gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3? exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and in particular the ROS scavenging activity, in particular, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that h Reg3?-transgenic mice resist better to DSS-induced colitis after antibiotherapy.

Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The present application relates to novel 3-imidazolines of formula (I?) and (I) below: (I?) (I) Wherein Ar1, Ar2, Ar3, and R1 to R6 are as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of carbapenemases. They are also useful as antibiotics themselves. The present invention also concerns a method for preparing more specifically the 3-imidazolines of formula (I). The present invention further relates to conjugates of said compounds with known antibiotics.

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: Device including a multileaf collimator, the multileaf collimator including an array of leaves and slits, the array having an alternation of leaves and slits and extending in a longitudinal direction, the longitudinal direction being defined as a direction extending from an entrance plane of the array toward an exit plane of the array, each leaf being located between two slits; the device having a source for emitting an incident electromagnetic beam or a source for emitting an incident beam of subatomic particles, the source being arranged to emit the beam in the direction of the entrance plane of the array, the multileaf collimator being arranged to obtain an arrangement of beams from the incident beam, and the arrangement of beams forms an alternation of high-energy lines and lower-energy lines.

Abstract: Process for in vitro diagnosis and/or monitoring and/or prognosis and/or theranosis of hepatic disorders from a biological sample originating from a subject, in which process the presence and/or the concentration of the marker ADH1B (SEQ ID NO.2) and/or the presence and/or the concentration of the combination of the markers ADH1B (SEQ ID NO.2) and ADH1A (SEQ ID NO.1) is determined.

Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.

Abstract: The present invention relates to a sensor for an electronic tongue or nose for analysing a sample or detecting a target. The sensor comprises a support, on one surface of which a plurality of sensitive areas are located, each sensitive area comprising at least one receptor and being capable of transmitting a measurable signal generated by the interaction of at least one constituent of the sample or one target with at least one receptor. The sensor is characterised in that it comprises at least three sensitive areas that differ from one another in terms of their respective receptor compositions, at least one of the sensitive areas comprising a mixture of at least two different receptors, while the two other sensitive areas each comprise at least one of the two receptors.

Abstract: The invention relates to a method for increasing the yield and biomass of a plant, by means of an increase in the expression of the L-aspartate oxidase in the plant. The method according to the invention allows an increase in the photosynthetic capacities of the plants as a result of an increase in the quantities of NAO and the derivatives thereof in said plants. The invention relates to the plants produced by such a method.

Abstract: A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

Abstract: The present invention relates to the design of novel molecules, referred to as “multi-target” molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the “multi-target” molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one “multi-target” molecule, and the use of such compositions in the treatment of cancer.

Abstract: Disclosed is an imaging device including a light source arranged so as to generate an optical signal, an optical support coupled to the light source and arranged so as to project a luminous excitation signal with a substantially constant light intensity, from the light source to a body to be observed during the use of the device, and an asynchronous camera coupled to the optical support and designed so as to generate a signal including, for each pixel of a first pixel matrix, a signal sequence representing asynchronous events corresponding to variations of the light backscattered by the body to be observed for the pixel.

Abstract: A system for “signal-on” electrochemical detection of molecules of interest and to a method implementing said system.

Abstract: The present invention relates to the field of Clostridium difficile infections. Methods of diagnosing, treating and preventing Clostridium difficile-associated disease and recurrent CDAD are disclosed herein.